Given that pRb status has been previously shown to determine sensitivity to Cdk4/6 inhibitors in other forms of cancer [27], the insensitivity to PD0332991 for Pax3:Foxo1a,p53,Rb1 tumors relative to Pax3:Foxo1a,p53 tumors was unexpected. The gene discussed is CDK4; the disease is cancer.